Recently, Arnold et al¹ proposed a combination therapy using TAK228 and trametinib for clinical testing in pediatric low-grade glioma (pLGG). There are, however, compelling reasons why the presented data are not convincing enough for a clinical trial with this combination. Here we will stress our most important concerns.

中文翻译：

---

评论：“ mTORC1 / 2激酶和MEK抑制剂的协同活性可抑制小儿低度神经胶质瘤的致瘤性和血管生成性”。

最近，Arnold等[ ^1]提出了一种使用TAK228和曲美替尼的联合疗法，用于儿科低度神经胶质瘤（pLGG）的临床测试。但是，存在令人信服的理由，说明所提供的数据不足以使这种组合的临床试验令人信服。在这里，我们将强调我们最重要的关切。